Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain diseases, CEO David Ricks said.
Eli Lilly Set to Become World's First $1 Trillion Drugmaker by Market Value
Eli Lilly is on the verge of becoming the world's first pharmaceutical company to reach a market value of $1 trillion. This milestone is driven by the
Drugmaker Lilly Slates Another $4.5B for Manufacturing and Drug Development Improvements
Eli Lilly is pouring another $4.5 billion into expanding manufacturing and development as the drugmaker rakes in billions from new product sales. The diabetes treatment maker said Wednesday that it will build a new center for advanced manufacturing and drug development a few miles from its Indianapolis headquarters.
Lilly to invest $4.5 billion on new facility to scale-up pipeline drug production
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on developing new ways to manufacture its drugs and increasing production of experimental medicines used in clinical studies.
Eli Lilly to build $4.5 billion Indiana facility for advanced drug manufacturing
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development facility in Lebanon, Indiana expected to open in late 2027.
Eli Lilly Plans $4.5 Billion Research Hub
Drugmaker Eli Lilly said it will spend $4.5 billion to build a new manufacturing research hub in Indiana, where it will develop new methods of producing complicated types of medicines. The new investm
Eli Lilly to Build $4.5B Research, Manufacturing Plant in Indiana
Eli Lilly will spend $4.5 billion to build a new plant in Indiana that combines research and manufacturing in a single location. Lilly on Wednesday said the plant, dubbed the Lilly Medicine Foundry, is the first of its kind and will give the Indianapolis drugmaker the ability to research new ways of producing medicines while also scaling up manufacturing of drug for clinical trials for its growing pipeline.
FiercePharma3d
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
USA Today2d
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...
ConsumerAffairs3d
Mountjaro, Zepbound removed from FDA's shortage list
Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...
This Is the Best Pharma Stock to Invest $1,000 in Right Now
In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
AOL28d
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for treating type 2 diabetes and obesity, respectively. But Mounjaro and ...
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...